BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 10, 2008
View Archived Issues
Onyx Will Develop Cancer Drug in $320M BTG Deal
Onyx Pharmaceuticals Inc. took another step toward building its pipeline by licensing an anticancer compound from London-based BTG plc, in a deal that could bring in as much as $320 million for the UK company. (BioWorld Today)
Read More
Tarceva Hits Endpoint in Phase III Maintenance Therapy NSCLC Trial
Read More
NewCo News: Stealth Blockmir Blocks miRNA One Target mRNA at a Time
Read More
Dingell, Waxman Fight for House Energy and Commerce Panel
Read More
Other News To Note
Read More